Summit Therapeutics Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC
Summit Therapeutics (NASDAQ:SMMT) announced positive overall survival results from its HARMONi-6 trial, showing ivonescimab plus chemotherapy reduced the risk of death by 34% compared to tislelizumab and chemotherapy. The median OS was 27.89 months for ivonescimab versus 23.69 months for tislelizumab.
Tickers: $SMMT
Topics: biotech cancer_treatment non-small_cell_lung_cancer pharmaceuticals